Substance / Medication

Vutrisiran

Overview

Active Ingredient
vutrisiran
RxNorm CUI
2604578

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review.
Karimi Mohammad Amin, Esmaeilpour Moallem Fatemeh, Gholami Chahkand Mohammad Sadra et al. · Front Neurol · 2024
PMID: 39286810Meta-AnalysisFull text (PMC)
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
Maurer Mathew S, Witteles Ronald M, Garcia-Pavia Pablo et al. · J Am Coll Cardiol · 2025
PMID: 40099776RCT
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana Marianna, Berk John L, Gillmore Julian D et al. · N Engl J Med · 2025
PMID: 39213194RCT
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial.
Sheikh Awais, Miao Zi Michael, Claggett Brian et al. · Eur J Heart Fail · 2025
PMID: 41159479RCTFull text (PMC)
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve Violaine, Perrain Valentine · Expert Opin Drug Discov · 2024
PMID: 38281068RCT
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Garcia-Pavia Pablo, Grogan Martha, Kale Parag et al. · Eur J Heart Fail · 2024
PMID: 38321786RCT
NEJM at ESC - Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Rubin Eric J, Leopold Jane, Morrissey Stephen · N Engl J Med · 2025
PMID: 39225280Other
Vutrisiran for ATTR Amyloidosis with Cardiomyopathy.
Merlini Giampaolo · N Engl J Med · 2025
PMID: 39752304Other
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.
Sheikh Farooq H, Habib Gilbert, Tang W H Wilson et al. · J Am Coll Cardiol · 2025
PMID: 40099774Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vutrisiran (substance)
SNOMED CT
41463211000001109
UMLS CUI
C5446328
RxNorm CUI
2604578

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.